Iclaprim: A novel dihydrofolate reductase inhibitor for skin and soft tissue infections

Future Microbiology

Volumn 4, Issue 2, 2009, Pages 131-143

  Morgan, Andrew ^a,b   Cofer, Christine ^a,c   Stevens, Dennis L ^a,c  

^a Boise VA Medical Center   (United States)

^b IDAHO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic; Dihydrofolate reductase inhibitor; Linezolid; Methicillin resistant Staphylococcus aureus; Resistant microorganism; Skin and skin structure infection; Vancomycin; Vancomycin resistant enterococcus

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN PLUS CLARITHROMYCIN; AZTREONAM; CEFTOBIPROLE; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; ICLAPRIM; KETOCONAZOLE; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; ORITAVANCIN; PIPERACILLIN PLUS TAZOBACTAM; TEFIBAZUMAB; TELAVANCIN; TIGECYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; PYRIMIDINE DERIVATIVE;

ABDOMINAL INFECTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BACTEREMIA; BACTERICIDAL ACTIVITY; BONE MARROW SUPPRESSION; BURNING SENSATION; CARDIOTOXICITY; CATHETER INFECTION; CLINICAL TRIAL; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DERMATITIS; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTROL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HUMAN; HYPOKALEMIA; HYPOTENSION; INFECTION; INJECTION SITE PAIN; INJECTION SITE SWELLING; INSOMNIA; LACTIC ACIDOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE DRUG DOSE; MYALGIA; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NONHUMAN; OPTIC NEURITIS; PHARMACODYNAMICS; PHLEBITIS; PHOTOSENSITIVITY; PNEUMONIA; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; REVIEW; SEPSIS; SEROTONIN SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SLEEP DISORDER; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS GROUP A; TASTE DISORDER; THROMBOPHLEBITIS; TREMOR; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING; BACTERIAL SKIN DISEASE; CHEMISTRY; MICROBIOLOGY;

ENTEROCOCCUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS SP. 'GROUP A';

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PYRIMIDINES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 63849164275     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.4.2.131     Document Type: Review

References (43)

1. Moellering RC Jr: The management of infections due to drug-resistant Gram-positive bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 2(12), 777-779 (2005).
2. Stevens DL, Bisno AL, Chambers HF: Practice guidelines for the diagnosis and management of skin and soft tissue infections. Clin. Infect. Dis. 41, 1373-1406 (2005).
3. American Thoracic Society and the Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171, 388-416 (2005).
4. Micek ST: Alternatives to vancomycin for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Clin. Infect. Dis. 45, S184-S190 (2007).
5. Akins RL, Haase KK: Gram-positive resistance: pathogens, implications, and treatment options. Pharmacotherapy 25(7), 1001-1010 (2005).
6. Bush K, Heep M, Macielag MJ, Noel GJ: Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy. Expert Opin. Investig. Drugs 16(4), 419-429 (2007).
7. Chambers HF, Hegde SS: Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative than vancomycin? Expert Rev. Anti-infect. Ther. 5(3), 335-337 (2007).
8. Schneider P, Hawser S, Islam K: Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioog. Med. Chem. Lett. 13, 4217-4221 (2003).
9. Petri WA Jr: Sulfonomides, trimethoprim-sulfamethoxazole, quinolones, and agents for urinary tract infections. In: The Pharmacological Basis of Therapeutics. Bruton L (Ed.). McGraw-Hill, USA (2006).
10. Oefner C, Bandera M, Dale GE 10. et al.: Mechanism of action of iclaprim (ICL) in Staphylococcus aureus. Presented at: The 18th Annual European Congress of Clinical Microbiology and Infectious Diseases Meeting. Barcelona, Spain, 19-22 April 2008.
11. Burri K, Greiveldinger-Poenaru S, Hoffner J, 11. Jaeger J, Gillessen D, Islam K: Iclaprim: a new synthetic route to support clinical studies. Presented at: The 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Washington DC, USA, 16-19 December 2005.
12. Brandt R, John BA, Henderson SJ, Harris SE, 12. Islam K: Absorption, pharmacokinetics, metabolism and excretion of iclaprim in healthy humans. Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Chicago, IL, USA, 17-20 September 2007.
13. Brandt R, Matthews A, Hall M, Islam K: 13. Interactions of iclaprim with human cytochrome P450 enzymes. Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Chicago, IL, USA, 17-20 September 2007.
14. Hadváry P, Neuenhofer D, Brandt R et al.: Influence of ketoconazole on the pharmacokinetics and safety of intravenous iclaprim. Presented at: 9th Jahreskongress für Klinische Pharmakologie. Kiel, Germany, 1-3 November 2007.
15. Zeman P, Trenk D, Cap M et al.: Lack of effect of the novel antibiotic iclaprim on the anticoagulant activity and the pharmacokinetics of warfarin in healthy subjects. Presented at: The 18th Annual European Congress of Clinical Microbiology and Infectious Diseases Meeting. Barcelona, Spain, 19-22 April 2008.
16. Ullmann U, Brandt R, Hadvary P, 16. Islam K: Dose linearity and gender-independent pharmacokinetics of intravenous iclaprim assessed in two randomized, double-blind and controlled cross-over studies. Presented at: The 18th Annual European Congress of Clinical Microbiology and Infectious Diseases Meeting. Barcelona, Spain, 19-22 April 2008.
17. Hawser S, Lociuro S, Islam K: 17. In vitro spectrum of activity of iclaprim against various Gram-positive and Gram-negative pathogens. Presented at: The Third International Symposium on Resistant Gram-positive Infections. Niagara-on-the-Lake, Ontario, Canada, 9-11 October 2006.
18. Hadváry P, de la Motte S, Klinger J, Islam K: Pharmacokinetics of iclaprim in subjects with varying degree of hepatic or renal insufficiency or obesity. Presented at: The 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, CA, USA, 4-7 October 2007.
19. Brandt R, Neuenhofer D, Thomsen T, Hadváry P, Islam K: Pharmacokinetics and bioavailability of iclaprim oral and intravenous formulations in humans. Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Chicago, IL, USA, 17-20 September 2007.
20. Jones RN, Fritsche TR, Hawser S, Islam K, Sader HS: In vitro activity of iclaprim, a novel diaminopyrimidine, tested against α-hemolytic streptococci from the USA and Europe: results from the International Study of Iclaprim Susceptibility (ISIS). Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Chicago, IL, USA, 17-20 September 2007.
21. Sader HS, Fritsche TR, Islam K, Hawser S, Jones RN: Antimicrobial activity of iclaprim tested against recent S. aureus clinical isolates: results from the International Study of Iclaprim Susceptibility (ISIS). Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Chicago, IL, USA, 17-20 September 2007.
22. Kohlhoff SA, Roblin PM, Reznik T, Hawser S, Islam K, Hammerschlag MR: In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimicrob. Agents Chemother. 48(5), 1885-1886 (2004).
23. Morrissey I, Hawser S: Activity of iclaprim against Legionella pneumophila. J. Antimicrob. Chemother. 4, 905-906 (2007).
24. Jacobs MR: AR-100, a novel diaminopyrimidine compound: activity against Haemophilus species and Moraxella catarrhali. Presented at: 42nd ICAAC Abstracts, Am. Soc. Microbiol. San Diego, CA, USA, 27-30 September 2002.
25. Morrissey I, Hawser S, Islam K, Williams L, Leakey A, Shackcloth J: Avity of iclaprim and comparators against atypical bacterial respiratory pathogens. Presented at: The 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Chicago, IL, USA, 14-17 September 2003.
26. Jones RN, Fritsche TR, Islam K, Hawser S, Sader HS: Antimicrobial activity of a novel dihydrofolate reductase, iclaprim, tested against clinical strains of Enterobacteriaceae: results from the International Study of Iclaprim Susceptibility (ISIS). Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Chicago, IL, USA, 17-20 September 2007.
27. Windau A: AR-100, a novel diaminopyrimidine compound: activity against Enterobacteriaceae. Presented at: The 42nd ICAAC Abstracts, Am. Soc. Microbiol. San Diego, CA, USA, 27-30 September 2002.
28. Fischer M, Weiss L, Scheidegger D, Bernardini F, Hawser S, Islam K: Iclaprim, a novel diaminopyrimidine antibiotic: in vitro and intracellular activity against Listeria monocytogenes. Presented at: The 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Chicago, IL, USA, 14-17 September 2003.
29. Hawser S, Weiss L, Fischer M: AR-100, a novel diaminopyrimidine compound: bactericidal activity and postantibiotic effect on Gram-positive pathogens. Presented at: 42nd ICAAC Abstracts, Am. Soc. Microbiol. San Diego, CA, USA, 27-30 September 2002.
30. Jones ME, Draghi DC, Grover PK, Hawser S, Islam K, Sahm DF: Bactericidal activity and post antibiotic effect of iclaprim (ICL) against Staphylococcus aureus (SA). Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Chicago, IL, USA, 17-20 September 2007.
31. Weiss L, Bihr M, Islam K, Lociuro S, Hawser S: Bactericidal activity of iclaprim against methicillin-sensitive and -resistant Staphylococcus aureus. Presented at: The 18th Annual European Congress of Clinical Microbiology and Infectious Diseases Meeting. Barcelona, Spain, 19-22 April 2008.
32. Krievens D, Leighton A, Brandt R et al.: Efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections: results of a Phase 2 study. Presented at: The 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Washington DC, USA, 16-19 December 2005.
33. Leighton A, Dankner WM, Stevens D, Islam K, Hadváry P: Safety of iclaprim in complicated skin and skin structure infections: ASSIST-1 results. Presented at: The 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, CA, USA, 4-7 October 2007.
34. Hawser S, Jones ME, Stevens D et al.: Microbiological efficacy of iclaprim against Staphylococcus aureus in complicated skin and skin structure infection (cSSSI): Preliminary results of ASSIST-1. Presented at: The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. Chicago, IL, USA, 17-20 September 2007.
35. Stevens D, Leighton A, Dankner WM, Islam K, Hadváry P: Efficacy of iclaprim in complicated skin and skin structure infections: Preliminary results of ASSIST-1. Presented at: The 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, CA, USA, 4-7 October 2007.
36. Dryden M, O'Hare MD, Sidarous E, Hadváry P, Islam K: Clinical efficacy of iclaprim in complicated skin and skin structure infection (cSSSI): Preliminary results from the ASSIST-2 clinical trial. Presented at: The 18th Annual European Congress of Clinical Microbiology and Infectious Diseases Meeting. Barcelona, Spain, 19-22 April 2008.
37. Jones ME, O'Hare MD, Burley C, Dankner WM, Islam K, Hadváry P: Preliminary results of the microbiological efficacy of iclaprim in complicated skin and skin structure infection (cSSSI) from the ASSIST-2 clinical trial. Presented at: The 18th Annual European Congress of Clinical Microbiology and Infectious Diseases Meeting. Barcelona, Spain, 19-22 April 2008.
38. Hadváry P, Dryden M, O'Hare MD et al.: Assessment of safety and tolerability profiles after iclaprim administration in complicated skin and skin structure infection (cSSSI) from the ASSIST-2 clinical trial (Arpida's Skin and Skin structure Infection Study-2). Presented at: The 18th Annual European Congress of Clinical Microbiology and Infectious Diseases Meeting. Barcelona, Spain, 19-22 April 2008.
39. Hadváry P, Dryden M, O'Hare MD, Dankner WM, Islam K: Analysis of the effect of iclaprim on the QT interval in the ASSIST-2 clinical trial. Presented at: The 18th Annual European Congress of Clinical Microbiology and Infectious Diseases Meeting. Barcelona, Spain, 19-22 April 2008.
40. Andrews J, Honeybourne D, Ashby J: Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. J. Antimicrob. Chemother. 60, 677-680 (2007).
41. Capriotti T: 'Superbugs' create need for novel antibiotics. Dermatol. Nurs. 19(1), 65-70 (2007).
42. Pan A, Lorinzotti S, Zoncada A: Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Patents Anti-infect. Drug Disc. 3(1), 10-33 (2008).
43. John JF Jr: Drug evaluation: tefibazumab - a monoclonal antibody against staphylococcal infection. Curr. Opin Mol. Ther. 8(5), 455-460 (2006).